Megan Cerullo is a New York-based reporter for CBS MoneyWatch covering small business, workplace, health care, consumer spending and personal finance topics. She regularly appears on CBS News 24/7 to ...

Memorial Day week will bring several closely watched economic reports, with investors eyeing fresh inflation data, a revised reading on first-quarter gross domestic product (GDP), and updates on ...

When the NFL releases the schedule for the upcoming regular season, it's a small form of torture. Sure, we get to see the roadmap for the upcoming year and all the great games we have in store for us, ...

After three days of marquee matchups being unveiled, the 2026 NFL regular season schedule has arrived with the league's full Thursday reveal. Week 1 -- and the season -- kicks off as usual with the ...

Crypto Week Ahead is a comprehensive list of what's coming up in the world of cryptocurrencies and blockchain, as well as the major macroeconomic events that will influence digital asset markets.

Sometimes, it's best to go by the numbers. Each week, Law.com is telling critical legal stories through data visualizations. In this week's roundup: How Florida's AI rules might be ushering in a new ...

AI success depends on whether enterprise data is ready, reachable, and close enough to the workloads that need it. In this eSpeaks episode, Dell Technologies’ Vrashank Jain explains why fragmented ...

Representatives of the crypto and banking industries are meeting with legislative staffers on Thursday and Friday to review revised compromise language on stablecoin yield provisions in the market ...

Global private‑equity firms Alpha Wave, Carlyle and Anchorage Capital are backing the $1 billion fundraise for the Indian telecom operator Bharti Airtel's data center unit. Nxtra has around 300MW of ...

Google Research announced this week that it had created a breakthrough artificial intelligence compression algorithm for large language models (LLMs), called TurboQuant. The company said the algorithm ...

Structure Therapeutics reported highly positive Phase 2 ACCESS II data for aleniglipron, achieving ~16% placebo-adjusted weight loss with strong statistical significance and no plateau. Aleniglipron’s ...

Structure Therapeutics has touted the 16% weight loss—about 39 pounds—seen by aleniglipron as the best results yet for an oral GLP-1 drug, as the obesity biotech readies the candidate for phase 3. The ...